Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-23	HK$23.00	+1.77%	54,500
26-09-23	HK$22.60	+8.24%	91,500
26-09-22	HK$20.88	+4.56%	90,300
26-09-21	HK$19.97	-3.15%	91,600
26-09-18	HK$20.62	+6.51%	149,300

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

19.34CNY

Average target price

19.66CNY

Spread / Average Target

+1.69%

Consensus

Net sales - Rate of surprise

Company calendar

Delayed Hong Kong S.E. 23:29:02 2026-09-23 EDT			5-day change	1st Jan Change
23.00 ^HKD	+1.77%		+18.80%	-24.54%

09-20	Medtide Inc.(SEHK:3880) added to S&P Global BMI Index	CI
08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	2.74B 3.2B 409M 359M 337M 308M 576M 39.14B 580M 4.05B 1.57B 19.95B 1.53B 1.5B 64.7B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.16B 2.53B 322M 283M 266M 243M 454M 30.87B 458M 3.19B 1.24B 15.74B 1.21B 1.18B 51.04B	EV / Sales 2026 *	3.61x	EV / Sales 2027 *	2.82x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

09-20	Medtide Inc.(SEHK:3880) added to S&P Global BMI Index	CI
08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-29	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-30	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
02-26	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
02-25	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI

Medtide Inc. Stock

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	+1.77%
1 week	+18.80%
Current month	+3.70%
1 month	-0.69%
3 months	-2.87%
6 months	+3.32%
Current year	-24.54%

1 week	19.38	23.8
1 month	17.64	23.8
Current year	17.64	30.46
1 year	17.64	33.18
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	2020-06-10
Li Jun Ding DFI	Director of Finance/CFO	50	2026-07-30
Wei Qun Xu DFI	Director of Finance/CFO	53	2020-09-30

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	2020-06-10
Xiang Li Li BRD	Director/Board Member	51	2022-01-26
Xiang Li BRD	Director/Board Member	63	2022-01-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/9/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
3/9/26	Xiang Li Li	Other	Director	68,201,112	48.0967%
3/9/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+1.77%	+18.80%	-24.84%	-	377M
LONZA GROUP AG	-0.18%	+4.35%	+4.23%	+31.79%	47.86B
IQVIA HOLDINGS INC.	-0.83%	-0.36%	+43.66%	+34.77%	44.46B
BEONE MEDICINES AG	-0.84%	+4.86%	+10.92%	+91.52%	41.85B
REVOLUTION MEDICINES, INC.	-1.10%	-2.64%	+331.49%	+535.80%	41.34B
CELLTRION, INC.	-0.62%	+0.11%	+1.12%	+46.02%	30.04B
MEDPACE HOLDINGS, INC.	-2.07%	+0.12%	+24.39%	+154.30%	17.59B
EUROFINS SCIENTIFIC SE	-3.55%	+1.95%	+21.97%	+38.83%	15.69B
ASCENDIS PHARMA A/S	-6.08%	-9.92%	-	-	15.6B
TEMPUS AI, INC.	-0.78%	+9.46%	-8.96%	-	13.93B
Average	-1.33%	+2.55%	+44.89%	+133.29%	26.87B
Weighted average by Cap.	-1.11%	+1.35%	+67.07%	+141.32%

	2026 *	2027 *
Net sales	599M 700M 89.19M 78.28M 73.59M 67.28M 126M 8.54B 127M 884M 343M 4.36B 335M 328M 14.12B	742M 867M 111M 97.07M 91.25M 83.42M 156M 10.59B 157M 1.1B 425M 5.4B 415M 406M 17.51B
Net income	-	-
Net Debt	-579M -677M -86.26M -75.71M -71.17M -65.07M -122M -8.26B -122M -855M -331M -4.21B -324M -317M -13.66B	-649M -758M -96.7M -84.87M -79.78M -72.94M -136M -9.26B -137M -958M -372M -4.72B -363M -355M -15.31B